newsfilter
← Latest News
PR Newswire·

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

"Very promising results." That is how REGENXBIO, Inc. (NASDAQ: RGNX) characterized its RGX-111 gene therapy candidate as recently as January 2025. By ...